Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Despite a minor sell-off by a firm, Gilead Sciences' stock soared 30.1% in Q4, exceeding analysts' expectations.
Meridian Investment Counsel Inc. slightly reduced its stake in Gilead Sciences Inc. by 0.9%, holding 21,167 shares worth $2.37 million.
Despite this, Gilead Sciences' stock saw a 30.1% increase in the fourth quarter.
The company reported earnings of $1.81 per share, exceeding analysts' expectations by $0.04.
Gilead Sciences' stock opened at $111.28 on Friday, with a market cap of $138.42 billion.
Analysts expect the company to post 7.95 EPS for the current year.
6 Articles
A pesar de una pequeña venta por parte de una empresa, las acciones de Gilead Sciences se dispararon un 30.1% en el cuarto trimestre, superando las expectativas de los analistas.